← ANALYST RATINGS · TIPRANKS
Merck & Company (MRK): analyst forecast and price target
Analyst consensus
Moderate Buy15 Buy6 Hold0 Sell
Ratings of 21 analysts in the last 3 months12-month forecast
Based on 21 price targets given in the last 3 months, the average target is $160, the highest $180, the lowest $105. The average is +9.6% from the last price of $146.
Analyst ratings 41
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Trung Huynh★★★★★★★★★★#475 · hits 76% · avg +21.9% | RBC Capital | $145 | Hold | −0.7% | Reiterated | 16.10.26on TipRanks 21:45 | after the close | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $165 | Buy | +13.1% | Reiterated | 15.10.26on TipRanks 07:50 | −1.8%next day +1.6% | ↗ |
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $164 → $151−7.9% | Hold | +3.5% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $164 → $143−12.8% | Hold | −2.0% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $161 → $149−7.5% | Hold | +2.1% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $159 → $146−8.2% | Hold | 0.0% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $166 → $150−9.6% | Hold | +2.8% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI PerPlexity Drug Manufacturers - GeneralPerPlexity SonarPro | TipRanks - PerPlexity | $165 → $151−8.5% | Hold | +3.5% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $170 | Buy | +16.5% | Reiterated | 12.10.26on TipRanks 09:06 | 0.0%next day −2.4% | ↗ |
| Daina Graybosch★★★★★★★★★★#12254 · hits 39% · avg −7.8% | Leerink Partners | $161 | Buy | +10.3% | Reiterated | 12.10.26on TipRanks 07:35 | 0.0%next day −2.4% | ↗ |
| Trung Huynh★★★★★★★★★★#475 · hits 76% · avg +21.9% | RBC Capital | $150 → $145−3.3% | Hold | −0.7% | Reiterated | 12.10.26on TipRanks 06:50 | 0.0%next day −2.4% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $145 | Hold | −0.7% | Reiterated | 12.10.26on TipRanks 05:55 | 0.0%next day −2.4% | ↗ |
| Emily Field★★★★★★★★★★#5009 · hits 45% · avg +1.9% | Barclays | $150 | Buy | +2.8% | Reiterated | 12.10.26on TipRanks 05:07 | 0.0%next day −2.4% | ↗ |
| Carter Gould★★★★★★★★★★#2194 · hits 53% · avg +6.3% | Cantor Fitzgerald | $145 | Hold | −0.7% | Reiterated | 11.10.26on TipRanks Oct 12 08:20 | 0.0%next day −2.4% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $175 | Buy | +19.9% | Reiterated | 09.10.26on TipRanks 09:15 | +1.7%next day 0.0% · 5 days +2.2% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $166 → $163−1.8% | Buy | +11.7% | Reiterated | 09.10.26on TipRanks 06:55 | +1.7%next day 0.0% · 5 days +2.2% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $352 → $170−51.7% | Buy | +16.5% | Reiterated | 08.10.26on TipRanks 07:35 | +0.1%next day +1.7% · 5 days +2.3% | ↗ |
| Carter Gould★★★★★★★★★★#2194 · hits 53% · avg +6.3% | Cantor Fitzgerald | $120 → $145+20.8% | Hold | −0.7% | Assigned | 08.10.26on TipRanks 07:20 | +0.1%next day +1.7% · 5 days +2.3% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $177 | Buy | +21.3% | Reiterated | 07.10.26on TipRanks 08:15 | +0.8%next day +0.1% · 5 days +4.2% | ↗ |
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | $150 → $165+10.0% | Buy | +13.1% | Reiterated | 05.10.26on TipRanks 07:40 | −4.0%next day +1.2% · 5 days +3.8% | ↗ |
| Asad Haider★★★★★★★★★★#1137 · hits 82% · avg +22.7% | Goldman Sachs | $160 | Buy | +9.6% | Reiterated | 30.09.26on TipRanks Oct 1 09:35 | −2.5%next day −1.2% · 5 days −3.6% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $170 | Buy | +16.5% | Reiterated | 30.09.26on TipRanks Oct 1 07:35 | −2.5%next day −1.2% · 5 days −3.6% | ↗ |
| Trung Huynh★★★★★★★★★★#475 · hits 76% · avg +21.9% | RBC Capital | $150 | Hold | +2.8% | Reiterated | 29.09.26on TipRanks Sep 30 21:45 | +0.6%next day −2.5% · 5 days −6.9% | ↗ |
| Louise Chen★★★★★★★★★★#1899 · hits 52% · avg +5.9% | Scotiabank | $155 → $180+16.1% | Buy | +23.3% | Reiterated | 29.09.26on TipRanks 07:50 | +0.6%next day −2.5% · 5 days −6.9% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $125 | Hold | −14.4% | Reiterated | 29.09.26on TipRanks 06:50 | +0.6%next day −2.5% · 5 days −6.9% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $170 | Buy | +16.5% | Reiterated | 25.09.26on TipRanks 09:15 | 0.0%next day +0.7% · 5 days −2.8% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $175 | Buy | +19.9% | Reiterated | 24.09.26on TipRanks 09:10 | 0.0%next day 0.0% · 5 days −2.4% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $166 | Buy | +13.7% | Reiterated | 23.09.26on TipRanks 07:07 | −1.2%next day 0.0% · 5 days −1.2% | ↗ |
| Steve Scala★★★★★★★★★★#1275 · hits 63% · avg +10.5% | TD Cowen | $137 → $155+13.1% | Hold | +6.2% | Reiterated | 22.09.26on TipRanks 13:30 | +1.0%next day −1.2% · 5 days +0.1% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $179 | Buy | +22.6% | Reiterated | 20.09.26on TipRanks 20:55 | +0.2%next day +1.0% · 5 days +0.5% | ↗ |
| Nico Chen★★★★★★★★★★#2913 · hits 59% · avg +9.8% | DBS | $180 | Buy | +23.3% | Reiterated | 11.09.26on TipRanks 12:55 | −1.4%next day +1.1% · 5 days +2.7% | ↗ |
| Rajesh Kumar★★★★★★★★★★#1587 · hits 62% · avg +14.5% | HSBC | $150 → $172+14.7% | Buy | +17.8% | Reiterated | 10.09.26on TipRanks 06:30 | −1.3%next day −1.4% · 5 days +1.7% | ↗ |
| Daina Graybosch★★★★★★★★★★#12254 · hits 39% · avg −7.8% | Leerink Partners | $127 → $161+26.8% | Buy | +10.3% | Assigned | 10.09.26on TipRanks Sep 9 06:20 | −0.2%next day −1.3% · 5 days −0.1% | ↗ |
| Vamil Divan★★★★★★★★★★#458 · hits 59% · avg +13.5% | Guggenheim | $146 → $170+16.4% | Buy | +16.5% | Reiterated | 08.09.26on TipRanks 07:30 | −0.7%next day −0.2% · 5 days −1.5% | ↗ |
| Emily Field★★★★★★★★★★#5009 · hits 45% · avg +1.9% | Barclays | $157 → $168+7.1% | Hold | +15.4% | Reiterated | 07.09.26on TipRanks Sep 8 04:30 | −0.7%next day −0.2% · 5 days −1.5% | ↗ |
| Courtney Breen★★★★★★★★★★#1339 · hits 85% · avg +18.9% | Bernstein | $105 | Hold | −28.1% | Reiterated | 07.09.26on TipRanks 12:20 | −0.7%next day −0.2% · 5 days −1.5% | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $150 → $170+13.3% | Buy | +16.5% | Assigned | 04.09.26on TipRanks 06:45 | −0.9%next day −0.7% · 5 days −2.4% | ↗ |
| Alexandria Hammond★★★★★★★★★★#7870 · hits 50% · avg +0.6% | Wolfe Research | $155 → $180+16.1% | Buy | +23.3% | Reiterated | 25.08.26on TipRanks 06:00 | +3.5%next day −2.2% · 5 days −3.7% | ↗ |
| Jasper Hellweg★★★★★★★★★★#2291 · hits 57% · avg +7.4% | Argus Research | $145 → $170+17.2% | Buy | +16.5% | Reiterated | 24.08.26on TipRanks Aug 25 08:16 | −0.9%next day +3.5% · 5 days −2.4% | ↗ |
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $143 → $164+14.7% | Hold | +12.4% | Downgrade | 20.08.26on TipRanks 05:05 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $137 → $164+19.7% | Hold | +12.4% | Reiterated | 20.08.26on TipRanks 05:05 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $139 → $161+15.8% | Hold | +10.3% | Reiterated | 20.08.26on TipRanks 05:05 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $132 → $159+20.5% | Hold | +8.9% | Reiterated | 20.08.26on TipRanks 05:05 | — | |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $143 → $166+16.1% | Hold | +13.7% | Downgrade | 20.08.26on TipRanks 05:05 | — | |
| AI PerPlexity Drug Manufacturers - GeneralPerPlexity SonarPro | TipRanks - PerPlexity | $140 → $165+17.9% | Hold | +13.1% | Reiterated | 20.08.26on TipRanks 05:05 | — | |
| Asad Haider★★★★★★★★★★#1137 · hits 82% · avg +22.7% | Goldman Sachs | $140 → $160+14.3% | Buy | +9.6% | Reiterated | 20.08.26on TipRanks Aug 19 12:55 | +12.4%next day −1.3% · 5 days +1.0% | ↗ |
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | — | Buy | — | Reiterated | 19.08.26on TipRanks 09:26 | +12.4%next day −1.3% · 5 days +1.0% | ↗ |
| Luisa Hector★★★★★★★★★★#3558 · hits 58% · avg +4.9% | Berenberg Bank | $127 | Hold | −13.0% | Reiterated | 05.08.26on TipRanks Aug 6 01:55 | +0.5%next day +0.2% · 5 days +3.2% | ↗ |
| Unknown Analyst | Jefferies | $138 | Buy | −5.4% | Reiterated | 19.05.26on TipRanks May 21 13:10 | +2.2%next day −2.1% · 5 days +3.0% | ↗ |
| Hans Engel★★★★★★★★★★#1835 · hits 58% · avg +11.1% | Erste Group | — | Hold | — | Reiterated | 05.05.26on TipRanks 07:00 | −0.8%next day −1.0% · 5 days −2.7% | ↗ |
| Natalya Davies★★★★★★★★★★#4625 · hits 89% · avg +16.4% | Rothschild & Co Redburn | $179 | Buy | +22.6% | Reiterated | 17.04.26on TipRanks 08:35 | +1.9%next day −1.5% · 5 days −6.6% | ↗ |
| Carter Gould★★★★★★★★★★#2194 · hits 53% · avg +6.3% | Cantor Fitzgerald | $120 | Hold | −17.8% | Reiterated | 29.03.26on TipRanks Mar 30 09:06 | −0.9%next day −1.1% · 5 days −3.3% | ↗ |
| James Shin★★★★★★★★★★#4468 · hits 57% · avg +7.3% | Deutsche Bank | $115 → $150+30.4% | Buy | +2.8% | Upgrade | 13.02.26on TipRanks 08:40 | +1.7%next day 0.0% · 5 days +1.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Merck & Company
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $161 at a price of $145 (+11.0%); now: $160 at $146 (+9.6%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Buy | 49 | 43 | 44 | 52 | 54 | 47 |
| Hold | 18 | 18 | 16 | 16 | 17 | 18 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $2.09 (from $1.80 to $2.26). Last quarter: $-0.13.
Sales
Next quarter’s sales estimate — $17.3B (from $16.8B to $17.6B). Last quarter: $16.6B.
Best top-analyst consensus in the sector · Healthcare
About Merck & Company
- CEO: Robert Davis
- Employees: 74,000
- 126 East Lincoln Avenue, Rahway, NJ, 07065, US
- www.merck.com
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Data from the stock’s TipRanks forecast page, read 14 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗